

**INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT**

Docket: 4239-61725	App: 09/830,748
Applicant: Kashmiri et al.	ATTACH TO #11
Filed: April 30, 2001	Art Unit: Not yet assigned

U.S. PATENT DOCUMENTS

Init.*	Number	Date	Name	Class	Sub	Filed
WD	4,816,567	3/28/89	Cabilly et al.	—	—	
WD	5,472,693	12/5/95	Gourlie et al.	1	1	
WD	5,482,040	1/9/96	Martin, Jr.			
WD	5,512,443	4/30/96	Schlom et al.			OCT 30 2002
WD	5,534,254	7/9/96	Huston et al.			
WD	5,585,089	12/17/96	Queen et al.			
WD	5,688,657	11/18/97	Tsang et al.			
WD	5,976,531	11/2/99	Mezes et al.			
WD	5,976,845	11/2/99	Mezes et al.	—	—	

TECH CENTER 1600
RECEIVED
OCT 30 2002
2000

U.S. PATENT APPLICATION DOCUMENTS

WD	08/961,309	10/30/97	Mezes et al.	—	—	
----	------------	----------	--------------	---	---	--


FOREIGN PATENT DOCUMENTS

WD	Number	Date	Country	Class	Sub	
WD	2,131,355 X	4/17/01	Canada	—	—	
WD	EP0239400 X	9/30/87	EPO	—	—	
WD	EP0365997 X	5/2/90	EPO	—	—	
WD	WO 89/00692 X	1/26/89	WIPO	—	—	
WD	WO 89/01783 X	3/9/89	WIPO	—	—	

EXAMINER:

DATE 5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Docket: 4239-61725	App: 09/830,748
		Applicant: Kashmiri et al.	
		Filed: April 30, 2001	Art Unit: Not yet assigned

	WO 90/04410 X	5/3/90	WIPO			
	WO 91/00295 X	1/10/91	WIPO			
	WO 93/12231 X	6/24/93	WIPO			
	WO 96/13594 X	5/9/96	WIPO			
	WO 97/26010 X	7/24/97	WIPO			
	WO 98/18809 X	5/7/98	WIPO			
	WO 99/43816 X	9/2/99	WIPO			
X	WO 00/26394 X	5/11/00	WIPO			

OTHER DOCUMENTS

LH		Abergel et al., "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab'," <i>Proteins: Structure, Function, and Genetics</i> 17:438-443, 1993. X
		Colcher et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies," <i>Cancer Research</i> 48:4597-4603, August 15, 1988. X
		Divgi et al., "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen," <i>Nucl. Med. Biol.</i> 21(1):9-15, 1994. X
		Hand et al., "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma," <i>Cancer Supplement</i> 73(3):1105-1113, February 1, 1994. X
		Iwahashi et al., "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity," <i>Molecular Immunology</i> 36:1079-1091, 1999. X
LH		Johnson et al., "Analysis of a Human Tumor-associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3," <i>Cancer Research</i> 46:850-857, February 1986. X

EXAMINER:

DATE

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

RECEIVED

OCT 30 2002

SAS:tjj 08/15/2002 4239-61725 E-258-98/2

TECH CENTER 1600/2800

Docket: 4239-61725

App: 09/830,748



**INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT**

Applicant: Kashmiri et al.

Filed: April 30, 2001

Art Unit: Not yet assigned

LA			Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with those from a Mouse," <i>Nature</i> 321:522-525, May 29, 1986.
			Kashmiri et al., "Generation, Characterization, and <i>in Vivo</i> Studies of Humanized Anticarcinoma Antibody CC49," <i>Hybridoma</i> 14(5):461-473, 1995. X
			Mulligan et al., "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma," <i>Clinical Cancer Research</i> 1:1447-1454, December 1995. X
			Muraro et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen," <i>Cancer Research</i> 48:4588-4596, August 15, 1988. X
			Padlan et al., "Identification of Specificity-determining Residues in Antibodies," <i>The FASEB Journal</i> 9:133-139, January 1995. X
			Padlan, "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains while Preserving their Ligand-binding Properties," <i>Molecular Immunology</i> 28(4/5):489-498, 1991. X
			Rixon et al., "Preferential Use of a H Chain V Region in Antitumor-associated Glycoprotein-72 Monoclonal Antibodies," <i>The Journal of Immunology</i> 151(11):6559-6568, December 1, 1993. X
			Sha et al., "A Heavy-chain Grafted Antibody that Recognizes the Tumor-associated TAG72 Antigen," <i>Cancer Biotherapy</i> 9(4):341-349, 1994. X
			Slavin-Chiorini et al., "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins," <i>Cancer Research (Supplement)</i> 55:5957s-5967s, December 1, 1995. X
DP			Tamura et al., "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only," <i>Journal of Immunology</i> 164(3):1432-1441, February 1, 2000. X

EXAMINER:

DATE

5/1/03


*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

SAS:tjj 08/15/2002 4239-61725 E-258-98/2

OCT. 3, 0 2002

OCT. 3, 0 2002

~~TECH CENTER 1600/2900~~



~~INFORMATION DISCLOSURE~~

STATEMENT

AUG 19 2002

S/BY APPLICANT

Docket: 4239-61725

App: 09/830,748

Applicant: Kashmiri et al.

Filed: April 30, 2001

Art Unit: Not yet assigned

Xiang et al., "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction," *Protein Engineering* 9(6):539-543, June 1996.

Xiang et al., "The Tyrosine Residue at Position 97 in the V_H CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen," *Cancer Biotherapy* 8(3):253-262, 1993.

EXAMINER:

DATE

5/1/03

*Examiner: Initial if considered, whether or not in conformance with MPEP 609; draw line through cite if not in conformance and not considered. Send copy.

Date Mailed: August 30, 2001

Sheet 1 of 2

RECEI

FORM 1449* O I P E INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)			Docket Number: 11613.32USWO	Application Number: 09/830,748
			Applicant: KASHMIRI ET AL.	
			Filing Date: 04/30/2001	Group Art Unit: UNKNOWN

DEC 1 0 2001
TECH CENTER 1600/2

ATTN TO # 13

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LM	4,816,567	03/28/1989	Cabilly et al.	—	—	
LM	5,472,693	12/05/1995	Gourlie et al.	—	—	
LM	5,482,040	01/09/1996	Martin, Jr.	—	—	
LM	5,512,443	04/30/1996	Schlom et al.	—	—	
LM	5,534,254	07/09/1996	Huston et al.	—	—	
LM	5,585,089	12/17/1996	Queen et al.	—	—	
LM	5,688,657	11/18/1997	Tsang et al.	—	—	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
LM	2,131,355	03/02/1996	CA	—	—		
LM	0 239 400	09/30/1987	EP	—	—		
LM	0 365 997	05/02/1990	EP	—	—		
LM	WO 89/00692	01/26/1989	PCT	—	—		
LM	WO 89/01783	03/09/1989	PCT	—	—		
LM	WO 90/04410	05/03/1990	PCT	—	—		
LM	WO 93/12231	06/24/1993	PCT	—	—		
LM	WO 96/13594	05/09/1996	PCT	—	—		
LM	WO 97/26010	07/24/1997	PCT	—	—		
LM	WO 98/18809	05/07/1998	PCT	—	—		
LM	WO 99/43816	09/02/1999	PCT	—	—		
LM	WO 00/26394	05/11/2000	PCT	—	—		


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

LM		Abergel, C. et al., "Crystallographic Studies and Primary Structure of the Antitumor Monoclonal CC49 Fab", <i>PROTEINS: Structure, Function, and Genetics</i> , Vol. 17, pp. 438-443 (1993).
LM		Colcher, D. et al., "Radioimmunolocalization of Human Carcinoma Xenografts with B72.3 Second Generation Monoclonal Antibodies", <i>Cancer Research</i> , Vol. 48, pp. 4597-4603 (August 15, 1988).

EXAMINER		DATE CONSIDERED	5/1/03
----------	--	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)		Docket Number: 11613.32USWO	Application Number: 09/830,748
		Applicant: KASHMIRI ET AL.	
		Filing Date: 04/30/2001	Group Art Unit: UNKNOWN



	Divgi, C. et al., "Clinical Comparison of Radiolocalization of Two Monoclonal Antibodies (mAbs) Against the TAG-72 Antigen", <i>Nucl. Med. Biol.</i> , Vol. 21, No. 1, pp. 9-15 (1994).
	Hand, P. et al., "Potential for Recombinant Immunoglobulin Constructs in the Management of Carcinoma", <i>CANCER Supplement</i> , Vol. 73, No. 3, pp. 1105-1113 (February 1, 1994).
	Iwahashi, M. et al., "CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity", <i>Molecular Immunology</i> , Vol. 36, pp. 1079-1091 (1999).
	Johnson, V. et al., "Analysis of a Human Tumor-Associated Glycoprotein (TAG-72) Identified by Monoclonal Antibody B72.3", <i>CANCER RESEARCH</i> , Vol. 46, pp. 850-857 (February 1986).
	Jones, P. et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse", <i>Nature</i> , Vol. 321, pp. 522-525 (May 29, 1986).
	Kashmiri, S. et al., "Generation, Characterization, and <i>in Vivo</i> Studies of Humanized Anticarcinoma Antibody CC49", <i>Hybridoma</i> , Vol. 14, No. 5, pp. 461-473 (1995).
	Mulligan, T. et al., "Phase I Study of Intravenous ¹⁷⁷ Lu-labeled CC49 Murine Monoclonal Antibody in Patients with Advanced Adenocarcinoma", <i>Clinical Cancer Research</i> , Vol. 1, pp. 1447-1454 (December 1995).
	Muraro, R. et al., "Generation and Characterization of B72.3 Second Generation Monoclonal Antibodies Reactive with the Tumor-associated Glycoprotein 72 Antigen", <i>Cancer Research</i> , Vol. 48, pp. 4588-4596 (August 15, 1988).
	Padlan, E., "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties", <i>Molecular Immunology</i> , Vol. 28, No. 4/5, pp. 489-498 (1991).
	Padlan, E. et al., "Identification of Specificity-Determining Residues in Antibodies", <i>Research Communications</i> , Vol. 9, pp. 133-139 (January 1995).
	Rixon, M. et al., "Preferential Use of a H Chain V Region in Antitumor-Associated Glycoprotein-72 Monoclonal Antibodies", <i>The Journal of Immunology</i> , Vol. 151, No. 11, pp. 6559-6568 (December 1, 1993).
	Sequence Listing from PCT Application PCT/US99/25552, "Variants of Humanized Anti-Carcinoma Monoclonal Antibody CC49", 12 pages (Filed October 29, 1999).
	Sha, Y. et al., "A Heavy-Chain Grafted Antibody that Recognizes the Tumor-Associated TAG72 Antigen", <i>Cancer Biotherapy</i> , Vol. 9, No. 4, pp. 341-349 (Winter 1994).
	Slavin-Chiorini, D. et al., "Biological Properties of Chimeric Domain-deleted Anticarcinoma Immunoglobulins", <i>Cancer Research (Suppl.)</i> , Vol. 55, pp. 5957s-5967s (December 1, 1995).
	Tamura, M. et al., "Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only", <i>The Journal of Immunology</i> , Vol. 164, No. 3, pp. 1432-1441 (February 1, 2000). X
	Xiang, J. et al., "Complementarity Determining Region Residues Aspartic Acid at H55, Serine at H95 and Tyrosines at H97 and L96 Play Important Roles in the B72.3 Antibody-TAG72 Antigen Interaction", <i>Protein Engineering</i> , Vol. 9, No. 6, pp. 539-543 (June 1996). X
X	Xiang, J. et al., "The Tyrosine Residue at Position 97 in the V _H CDR3 Region of a Mouse/Human Chimeric Anti-Colorectal Carcinoma Antibody Contributes Hydrogen Bonding to the TAG72 Antigen", <i>Cancer Biotherapy</i> , Vol. 8, No. 3, pp. 253-262 (Fall 1993). X



23552

PATENT TRADEMARK OFFICE

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>5/1/03</i>
----------	--------------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.